Alle verbonden artikelen

Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Auteurs : Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A
Jaar : 2015
Journal : Breast Cancer Res. Treat.
Volume : 149(1)
Pagina's : 313

Evolution In the therapeutic strategy of localized resectable pancreatic ductal adenocarcinoma.

Auteurs : Van Daele D, Puleo F, Dumont R, Polus M, Loly C, Martinive P, Meunier P, Collignon J, Hendlisz A, Maréchal R, Louis E, Van Laethem JL
Jaar : 2015
Journal : Rev Med Suisse
Volume : 11
Pagina's : 1543-8

Evolving paradigms in multifocal breast cancer.

Auteurs : Salgado R, Aftimos P, Sotiriou C, Desmedt C
Jaar : 2015
Journal : Semin. Cancer Biol.
Volume : 31C
Pagina's : 111-118

St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists.

Auteurs : Ignatiadis M, Buyse M, Sotiriou C
Jaar : 2015
Journal : Ann Oncol
Volume : 26(8)
Pagina's : 1519-20

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.

Auteurs : Cortes J, Hudgens S, Twelves C, Perez EA, Awada A, Yelle L, McCutcheon S, Kaufman PA, Forsythe A, Velikova G
Jaar : 2015
Journal : Breast Cancer Res Treat
Volume : 154
Pagina's : 509-20

Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.

Auteurs : Amzerin M, Mokrim M, Errihani H, Piccart-Gebhart M
Jaar : 2015
Journal : J Med Case Rep
Volume : 9
Pagina's : 5

Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.

Auteurs : Van Keymeulen A, Lee MY, Ousset M, Brohée S, Rorive S, Giraddi RR, Wuidart A, Bouvencourt G, Dubois C, Salmon I, Sotiriou C, Phillips WA, Blanpain C
Jaar : 2015
Journal : Nature
Volume : 525(7567
Pagina's : 119-23

Adjuvant systemic therapy in breast cancer: quo vadis?

Auteurs : Sonnenblick A, Piccart-Gebhart M
Jaar : 2015
Journal : Ann Oncol
Volume : 26(8)
Pagina's : 1629-34

CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer-Where Did It Start and Where Are We Now?

Auteurs : Gingras I, Desmedt C, Ignatiadis M, Sotiriou C
Jaar : 2015
Journal : Clin Cancer Res
Volume : 21
Pagina's : 4743-6

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Auteurs : Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart-Gebhart M
Jaar : 2015
Journal : Ann Oncol
Volume : 26
Pagina's : 1547-73

A prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer.

Auteurs : Gil T, Aoun F, Cabri P, Maisonobe P, Van Velthoven R
Jaar : 2015
Journal : Ther Adv Urol
Volume : 7(3)
Pagina's : 116-24

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?

Auteurs : Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, Kaufman B, Paluch-Shimon S, Gewefel H, Gallerani E, Abulkhair O, Pistilli B, Warner E, Saloustros E, Perey L, Zaman K, Rabaglio M, Gelber S, Gelber Rd, Godhirsch A, Korde L, Azim HA, Partridge AH
Jaar : 2015
Journal : Breast
Volume : 24(3)
Pagina's : 201-7

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.

Auteurs : Perez EA, Awada A, OShaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J
Jaar : 2015
Journal : Lancet Oncol
Volume : 16
Pagina's : 1556-68

'New' metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy, Breast Cancer Research 2015, 17: 150

Auteurs : Twelves C, Cortes J, Kaufman PA, Yelle L, Awada A, Binder T, Olivo M, O Shaughnessy J, Jove M, Perez EA
Jaar : 2015
Journal : Breast Cancer Res
Volume : 17
Pagina's : 150

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.

Auteurs : Sonnenblick A, Brohée S, Fumagalli D, Vincent D, Venet D, Ignatiadis M, Salgado R, Van den Eynden G, Rothé F, Desmedt C, Neven P, Loibl S, Denkert C, Joensuu H, Loi S, Sirtaine N, Kellokumpu-Lehtinen PL, Piccart-Gebhart M, Sotiriou C
Jaar : 2015
Journal : BMC Med
Volume : 13(1)
Pagina's : 177

Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy.

Auteurs : Azim HA, Vingiani A, Peccatori F, Viale G, Loi S, Pruneri G
Jaar : 2015
Journal : Breast
Volume : 24(3)
Pagina's : 290-3

Thrombo-embolic events in cancer patients with impaired renal function

Auteurs : Elalamy I, Canon JL, Bols A, Lybaert W, Duck L, Jochmans K, Bosquée L, Peeters M, Awada A, Clement P, Holbrechts S, Baurain JF, Mebis J, Nortier J
Jaar : 2015
Journal : Belgian J Medical Oncology
Volume : 9(2)
Pagina's : 53-60

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.

Auteurs : Sonnenblick A, Francis PA, Azim HA, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart-Gebhart M, Crown J
Jaar : 2015
Journal : Eur. J. Cancer
Volume : 51(12)
Pagina's : 1481-9

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

Auteurs : Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J, Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Pusztai L, Ellis C, Eidtmann H, Arribas J, Cortes J, de Azambuja E, Piccart-Gebhart M, Baselga J
Jaar : 2015
Journal : Clin Cancer Res
Volume : 21(3)
Pagina's : 569-76

Checkpoint inhibitors in bladder and renal cancers: results and perspectives.

Auteurs : Aoun F, Kourie HR, Sideris S, Roumeguère T, Van Velthoven R, Gil T
Jaar : 2015
Journal : Immunotherapy
Volume : 7
Pagina's : 1259-71